EU Clinical Trial 2018-004727-37

A Phase I/IIa open-label, multi-center study to evaluate the safety, tolerability, whole-body distribution, radiation dosimetry and anti-tumor activity of [177Lu]-NeoB administered in patients with advanced solid tumors known to overexpress gastrin-releasing peptide receptor (GRPR).  Feb 18, 2019

Main objective of the trial: Phase I: • To identify the maximum tolerated dose (MTD) and/or Recommended Phase II dose (RP2D) of [177Lu]-NeoB Phase IIa: • To assess the Disease Control Rate (DCR) at week 20 of [177Lu]-NeoB at the RP2D


NeoB [177Lu]-NeoB [177Lu]-NeoB solution for infusion [68Ga]-NeoB 50 µg, kit for radiopharmaceutical preparation

JSON preview

Similar records


Source:  EMA Last updated:  May 30, 2019

From, a database of the European Medicines Agency. This record may not reflect the most current and accurate data available from the EMA.